Design and Synthesis of Edaravone Derivatives Containing 6‐(4‐aminophenyl)‐4,5‐dihydropyridazin‐3(2 H )‐one as Bifunctional Anti‐ischemic Stroke Agents
Authors:
- 9 May 2025
- journal article
- Published by Wiley in Chemistry & Biodiversity
- Vol. 22 (9) , e202500516
Abstract
Ischemic stroke gravely endangers human health. To develop novel drugs with antiplatelet and neuroprotective functions for ischemic stroke, edaravone derivatives CT01–CT20 , containing 6‐(4‐aminophenyl)‐4,5‐dihydropyridazin‐3(2 H )‐one, were synthesized from materials like dimethyl butynedioate, ethyl acetoacetate, and diethyl 1,3‐acetonedicarboxylate, via cyclization, hydrolysis, and condensation. Among them, CT16 exhibited outstanding antiplatelet activity (IC 50 = 6.72 µM), absent in edaravone. It also surpassed edaravone in 1,1‐diphenyl‐2‐picrylhydrazyl radical scavenging (EC 50 = 30.80 µM) and protecting PC12 cells from H₂O₂ damage. In vivo, CT16 effectively reduced carotid artery thrombosis in rats and enhanced blood flow. In the middle cerebral artery occlusion reperfusion injury model, it shrank infarct size, improved neurological scores, increased cerebral blood flow, and lessened brain edema. Preliminary safety tests indicated CT16 didn't alter rat blood biochemistry or organ pathology, with a low bleeding risk as an antiplatelet agent. Molecular docking suggested it may inhibit phosphodiesterase 3A to achieve an antiplatelet effect. In conclusion, CT16 has both antiplatelet aggregation and neuroprotective effects and is a potential candidate compound for the treatment of ischemic stroke.Keywords
This publication has 32 references indexed in Scilit:
- Edaravone for Acute Ischemic Stroke: A Systematic Review and Meta-analysisClinical Therapeutics, 2022
- Advances in stroke pharmacologyPharmacology & Therapeutics, 2018
- Neuroprotective effect of trans-N-caffeoyltyramine from Lycium chinense against H2O2 induced cytotoxicity in PC12 cells by attenuating oxidative stressBiomedicine & Pharmacotherapy, 2017
- Precision Stroke Animal Models: the Permanent MCAO Model Should Be the Primary Model, Not Transient MCAOTranslational Stroke Research, 2017
- The therapeutic journey of pyridazinoneEuropean Journal of Medicinal Chemistry, 2016
- The cysteine releasing pattern of some antioxidant thiazolidine-4-carboxylic acidsEuropean Journal of Medicinal Chemistry, 2016
- Synthesis of new 4,5-3(2H)pyridazinone derivatives and their cardiotonic, hypotensive, and platelet aggregation inhibition activitiesArchives of Pharmacal Research, 2010
- Neuroprotection for ischemic stroke: Past, present and futureNeuropharmacology, 2008
- An optimized murine model of ferric chloride-induced arterial thrombosis for thrombosis researchThrombosis Research, 2005
- Y-590 (A new pyridazinone derivative), a potent anti-thrombotic agent — II. Inhibition of platelet phosphodiesteraseThrombosis Research, 1984